Pfizer-BioNTech is leading and making its way through! As we all know by now, Pfizer secured a green light in the UK and Bahrain long back.
The UK was the first Nation of the globe to approve of Pfizer-BioNTech’s COVID-19 vaccine candidate, which was ringed in by a thorough work up by the Medicines and Healthcare Products Regulatory Agency (MHRA). Last mentioned, Bahrain also acknowledged the approval of the vaccine candidate after its full-body analysis and review of the data provided.
But, today as stated in the latest headlines all over the leading News channels: Pfizer becomes the first company to beat the bushes in emergency use approval of its vaccine candidate in India as well.
The company desired approval from the Drugs Controller General of India for emergency use accreditation.
Last Friday, during an all- party meet, the Prime Minister, Narendra Modi spelled out experts to say that, ‘India could have the first coronavirus vaccine in weeks and that eight vaccines will be manufactured in India itself.’ Since then, the development is symbolic.
As narrated by a PTI report: On December 4, Pfizer submitted an application in terms to track down permission for import and distribution of the vaccine in India. Adding to that, it appealed a permit to waive the clinical trials on Indian populations- as per the the special boards under the New Drugs and Clinical Trials Rules of 2019- and yet to instead get an instant approval for emergency use.
India was in a tall tale with Pfizer-BioNTech regarding its COVID-19 vaccine candidate. However, Moderna wasunasked for its experimental COVID-19 vaccine- garnered by Director of AIIMS Delhi, namely Dr. Randeep Guleria.
Because of the corona virus and its staggering spread, there has been an addition in the history of vaccines– the approval of Pfizer’s vaccine candidate came into existence in 10 months only, post its development; it is the shortest and fastest timeline yet.
Have a look at the Statistical View of all the known COVID-19 vaccine candidates:
Of all the vaccine candidates- Pfizer, BioNTech, Moderna, and Sputnik V are the only ones that have efficacy over 90 per cent.
AstraZeneca and the University of Oxford’s vaccine candidate, along with India’s Serum Institute, have also achieved an efficacy of 70 per cent during the primal analysis of its COVID-19 trial partakers.